___

• 1) Sipos W, Pietschmann P, Rauner M, Ke rs c h a n -Sc h i n d l K, Pa ts c h J. Pathophysiology of osteoporosis.Wien Med Wochenschr 2009;159 (2):230-4. 2) Vilela P, Nunes T. Osteoporosis. Neuroradiology 2011;53:185-9. 3) S a n d h u S K , H amp s o n G . T h e pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol 2011;64(3):1042-50. 4) Epstein S. Update of current therapeutic o p t i o n s f o r t h e t r e a t m e n t o f postmenopausal osteoporosis. Clin Ther 2006;28(5):151-73. 5) Guyatt GH, Cranney A, Griffith L, Walter S, Krolicki N, Favus M, Rosen C. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrine Rev 2002;23(4):570- 78. 6) Pols HA, Felsenberg D, Hanley DA, Stepan J, et al. Multinational, placebocontrolled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Foxamax International Trial Study Group. Osteoporos Int 1999;9(5):461-8. 7) Denhardt DT, Noda M. Osteopontin expression and function: role in bone r e m o d e l i n g . J C e l l B i o c h e m 1998;72(2):92-102. 8) Ihara H, Denhardt DT, Furuya K, et al. Parathyroid hormone-induced bone resorption does not occur in the absence of o s t e o p o n t i n . J B i o l C h e m 2001;276(3):13065-71. 9) Gögebakan B, Igci YZ, Arslan A, Igci M, Erturhan S, Oztuzcu S, et al. Association between the T-593A and C6982T polymorphisms of the osteopontin gene and risk of developing nephrolithiasis. Arch Med Res 2010;41(6):442-8. 10) Ohmori R. Plasma osteopontin levels are associated with the presence and extend of coronary artery disease. Atherosclerosis 2003;170(4):333-37. 11) Vordermark D, Said HM, Katzer A, et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of E L I S A s y st e m . B M C C a n c e r 2006;6(2):207. 12) Chang IC, Chiang TI, Yeh KT, et al. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 2010;21(4):1401-9. 13) Daniela F, Cosmina B, Adriana A, Siao-pin S, Alexandra C, Laura M. The Value of Osteopontin in the Assessment of Bone Mineral Density Status in Postmenopausal Women. J Investig Med 2013;61(4):15-21. 14) Chiang TI, Chang IC, Lee HS, et al. Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos Int 2011;22(2):577-85. 15) Schneider DL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. In The Management of The Menopause (ed): J Studd. Parthenon Publishing, New York, p.135,1998. 16) Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 2011;12(4):209. 17) Dominquez LJ, Di Bella G, Belvedere M, Barbagallo M. Physiology of the aging bone a n d m e c h a n is m s o f a c t i o n o f bisphosphona t e s. Bioge rontology 2011;12(4):397-408. 18) Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112(1):281–9. 19) Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17(4):1–10. 20) Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005;20(2):2097–104. 21) Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 2005;16(3):842–8. 22) Compston J. Monitoring osteoporosis treatment. Best Pract Res Clin Rheumatol 2009;23(6):781-8. 23) Miller PD. Monitoring osteoporosis therapies. Curr Osteoporos Rep 2007;5:38- 43. 24) Yoshitake H, Rittling SR, Denhardt DT, et al. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 1999;96(2):8156-60. 25) Franze´n A, Hultenby K, Reinholt FP, et al. Altered osteoclast development and function in osteopontin deficient mice. J Orthop Res. 2008;26(2):721-8. 26) Shapses SA, Cifuentes M, Spevak L, Chowdhury H, Brittingham J, Boskey AL, Denhardt DT. Osteopontin facilitates bone resorption, decreasing bone mineral crystallinity and content during calcium d e f i c i e n c y . C a l c i f T i s s u e I n t 2003;73(1):86–92. 27) Ishijima M, Tsuji K, Rittling SR, Yamashita T, Kurosawa H, Denhardt DT, Nifuji A, Ezura Y, Noda M Osteopontin is required for mechanical stress-dependent signals to bone m a r r o w c e l l s . J E n d o c r i n o l 2007;193(2):235–243. 28) Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB. Osteopontin deficiency and aging on nanomechanics of Mouse bone. J Biomed Mater Res 2007;83(1):136–144. 29) Duvall CL, Taylor WR, Weiss D, et al. Impaired angiogenesis, early callus formation, and late stage remodeling in fracture healing of osteopontin-deficient mice. J Bone Miner Res. 2007;22(1):286-97. 30) Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, et al. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopaus a l women. BMC Musculoskeletal Disorders 2011;12(4):209. 31) Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosisoptimizing efficacy in clinical practice. Clin Interv Aging 2008;3(2):279-97. 32) Arlot ME, Jiang Y, Genant HK, Zhao J, BurtPichat B, Roux JP et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008;223(1):215-22. 33) Rittling SR, Matsumoto HN, McKee MD, et al. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J Bone Miner Res 1998;13(2):1101-11. 34) Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22(3):391- 420.